1217
SHANGHAI , Dec. 17, , a biopharmaceutical company focused on innovative drug research and development, clinical development, manufacturing and commercialization, today announced that the China National Medical Products Administration has formally accepted the New Drug Authorization Application NDA for VELSIPITY ® for the treatment of patients with moderate to severe active ulcerative colitis UC. Itramod is a oncedaily oral firstline advanced therapy that is not only easy to use and has good efficacy, but also has a good safety profile.
As a blockbuster product of Everest Medicines in the field of autoimmune new zealand mobile number list diseases, Itramod obtained new drug approval in Macau, China and Singapore in the first half of this year, and was launched in the GuangdongHong KongMacao Greater Bay Area through the "Hong Kong and Macao Drug and Medical Device Access" policy in October this year, becoming Everest Medicines' third commercialized new drug. In December this year, the first prescription of Itramod was issued at the Kiang Wu Hospital in Macau, China, and it officially began to benefit Asian patients. Genting Everest has also submitted a new drug marketing authorization application for itramod in Hong Kong, China and has been formally accepted.